ArticleDiabetes & vascular disease research
Identification of circulating biomarkers and immune subtypes for diabetic retinopathy through multi-cohort integrative analysis.
Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PurposeTo elucidate the dynamic molecular evolution and immune heterogeneity in diabetic retinopathy (DR) and identify diagnostic biomarkers.MethodsMulti-omics integrative analysis was performed on peripheral blood transcriptomic data from diabetic patients with and without DR. Techniques included differential expression analysis, immune infiltration profiling, unsupervised clustering, and LASSO regression for biomarker selection. Findings were validated in an independent high-glucose-treated endothelial cell model.ResultsDR progression exhibits staged molecular evolution from diabetes (immune suppression) to early DR (cell cycle inhibition, immune burst) and advanced DR (metabolic stress, persistent immune dysregulation). Six co-downregulated immune modules indicated systemic immune suppression. Patients were classified into three immune subtypes: vascular-inflammatory, metabolic disorder, and oxidative stress-tissue remodeling. A diagnostic model based on IK, PLBD2, FLNA, H6PD, and ZMAT2 achieved an AUC of 0.876 for distinguishing DR from diabetes alone.ConclusionThis study delineates the dynamic molecular landscape and immune heterogeneity of DR, providing a potential multi-gene diagnostic signature and a framework for patient stratification, which may facilitate early detection and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.